<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rimantadine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rimantadine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Rimantadine: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9866" href="/d/html/9866.html" rel="external">see "Rimantadine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11276" href="/d/html/11276.html" rel="external">see "Rimantadine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1055276"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent, Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F216952"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="842415b2-b3d8-493d-87b0-c197ac4d7c4b">Influenza A, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A, prophylaxis:</b>
<b>Note:</b> Rimantadine should NOT be used for prophylaxis of influenza A infection due to high resistance rates (AAP 2020; CDC 2021; IDSA [Uyeki 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤9 years: Oral: 5 mg/kg/dose once daily; maximum dose: 150 mg/dose (IDSA/PIDS [Bradley 2011]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Oral: 100 mg twice daily or 200 mg once daily (IDSA/PIDS [Bradley 2011]; manufacturer's labeling).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e0bbb63-d51c-47e5-ae33-43b20ebe0f38">Influenza A infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A infection, treatment:</b>
<b>Note:</b> Rimantadine should NOT be used for treatment of influenza A infection due to high resistance rates (AAP 2020; CDC 2021; IDSA [Uyeki 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤9 years: Limited data available: Oral: 3.3 mg/kg/dose twice daily for 7 days or until 24 to 48 hours after symptoms resolution; maximum dose: 75 mg/dose (IDSA/PIDS [Bradley 2011]).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Limited data available: Oral: 100 mg twice daily or 200 mg once daily for 7 days, or until 24 to 48 hours after symptom resolution (IDSA/PIDS [Bradley 2011]).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51220126"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Nondialyzable.</p></div>
<div class="block dohp drugH1Div" id="F51220127"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block doa drugH1Div" id="F216941"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9866" href="/d/html/9866.html" rel="external">see "Rimantadine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f4b05f5-986c-4578-a8eb-6a930a5e22ee">Influenza A, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Influenza A, prophylaxis or treatment:</b> The CDC and the Infectious Diseases Society of America do not recommend rimantadine for the treatment or prophylaxis of influenza A infection due to high resistance rates (CDC 2021; IDSA [Uyeki 2019]).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F216908"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Insomnia (2% to 3%), lack of concentration (≤2%), dizziness (1% to 2%), nervousness (1% to 2%), fatigue (1%), headache (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (3%), anorexia (2%), vomiting (2%), xerostomia (2%), abdominal pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal gait, agitation, altered sense of smell, ataxia, bronchospasm, cardiac failure, confusion, cough, depression, diarrhea, drowsiness, dysgeusia, dyspepsia, dyspnea, euphoria, hallucination, heart block, hyperkinesia, hypertension, lactation, palpitations, pallor, pedal edema, seizure, skin rash, syncope, tachycardia, tinnitus, tremor</p></div>
<div class="block coi drugH1Div" id="F216922"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to rimantadine, other adamantanes (eg, amantadine), or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F216905"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with a history of seizure disorder; an increase in seizure incidence may occur. Discontinue if seizures occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: The elderly are at higher risk for CNS (eg, dizziness, headache, weakness) and gastrointestinal (eg, nausea/vomiting, abdominal pain) adverse events; dosage adjustment is recommended in patients &gt;65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Resistance: May develop during treatment; viruses exhibit cross-resistance between amantadine and rimantadine.</p></div>
<div class="block foc drugH1Div" id="F216915"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block geq drugH1Div" id="F216901"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F216924"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (riMANTAdine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $3.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F10297270"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">Rimantadine 10 mg/mL Suspension:</p>
<p style="text-indent:-2em;margin-left:2em;">To prepare suspension, 10 mL of Ora-Sweet® will be required for every 100 mg tablet of rimantadine. (Do not prepare more than a 14-day supply). </p>
<p style="text-indent:-2em;margin-left:2em;">- Calculate the total dose needed (daily dose x number of days = mg of rimantadine needed) and round the final mg of rimantadine needed up to the next 100 mg (eg, 750 mg would be 800 mg, or eight 100 mg tablets).</p>
<p style="text-indent:-2em;margin-left:2em;">- Calculate the total volume of Ora-Sweet® by taking the rounded mg of rimantadine and dividing by 10 mg/mL (eg, 800 mg divided by 10 mg/mL = 80 mL).</p>
<p style="text-indent:-2em;margin-left:2em;">- Grind required number of tablets in mortar and triturate to a fine powder. Slowly add <sup>1</sup>/<sub>3</sub> of the total volume of Ora-Sweet® to the mortar and triturate until a uniform suspension is achieved.</p>
<p style="text-indent:-2em;margin-left:2em;">- Transfer to an amber glass or PET plastic bottle. Slowly add another <sup>1</sup>/<sub>3</sub> of the total volume of Ora-Sweet® to the mortar, rinsing the mortar, then transferring the contents into the bottle. Repeat using the final 1/3 of Ora-Sweet®. Add additional vehicle to bottle, if needed, to achieve the total calculated volume.</p>
<p style="text-indent:-2em;margin-left:2em;">- Shake well to ensure homogeneous suspension. Some inert ingredients in the tablet may be insoluble.</p>
<p style="text-indent:-2em;margin-left:2em;">- Label: Shake gently prior to each use.</p>
<p style="text-indent:-2em;margin-left:2em;">- Suspension is stable for 14 days when stored at room temperature (25°C/77°F).</p></div>
<div class="block admp drugH1Div" id="F52613802"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken without regard to food.</p></div>
<div class="block sts drugH1Div" id="F4625353"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53568643"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prophylaxis of influenza A virus infection (FDA approved in ages ≥1 year and adults); treatment of influenza A viral infection (FDA approved in ages ≥17 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Rimantadine is not recommended for prophylaxis or treatment of influenza A due to high resistance rates (AAP 2020; CDC 2021; IDSA [Uyeki 2019]).</p></div>
<div class="block mst drugH1Div" id="F216965"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">RiMANTAdine may be confused with amantadine, raNITIdine, Rimactane </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flumadine may be confused with fludarabine, flunisolide, flutamide</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300002"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F216910"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid administration of live influenza virus vaccine (LAIV) within 2 weeks before or 48 hours after administration of antiviral agents. Consider avoiding LAIV if peramivir was given within the last 5 days or baloxavir was given within the last 17 days.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F216925"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies. Untreated influenza infection is associated with an increased risk of adverse events to the fetus and an increased risk of complications or death to the mother. Neuraminidase inhibitors are currently recommended for the treatment or prophylaxis influenza in pregnant women and women up to 2 weeks postpartum. Appropriate antiviral agents are currently recommended as an adjunct to vaccination and should not be used as a substitute for vaccination in pregnant women (CDC 60[1] 2011; CDC March 13, 2014; CDC January 2015).  </p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to refer women exposed to influenza vaccine, or who have taken an antiviral medication during pregnancy to the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at 1-877-311-8972. </p></div>
<div class="block pha drugH1Div" id="F216904"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Exerts its inhibitory effect on three antigenic subtypes of influenza A virus (H1N1, H2N2, H3N2) early in the viral replicative cycle, possibly inhibiting the uncoating process; it has no activity against influenza B virus and is two- to eightfold more active than amantadine</p></div>
<div class="block phk drugH1Div" id="F216921"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Antiviral activity: No data exist establishing a correlation between plasma concentration and antiviral effect </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Well absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Children: 289 L (Anderson 1987); Adults: 727 to 768 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein Binding: ~40%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic via hydroxylation and glucuronidation</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 5 to 8 years: 24.8 ± 9.4 hours (Anderson 1987)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: 25.4 hours (range: 13 to 65 hours); Elderly (71 to 79 years of age): 32 hours (range: 20 to 65 hours)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;25% as unchanged drug) </p></div>
<div class="block phksp drugH1Div" id="F51220984"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: C<sub>max</sub>, AUC<sub>0 to Tau</sub>, and half-life increased by 75%, 81%, and 49%, respectively, in patients with severe renal impairment (CrCl 5 to 29 mL/minute). There was a 1.6-fold increase in half-life and 40% decrease in apparent Cl of rimantadine in hemodialysis patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC was about 3-fold larger, elimination half-life was about 2-fold longer, and apparent Cl was 50% lower in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In patients older than 70 years of age, the average AUC, peak concentrations, and elimination half-life at steady state were 20% to 30% higher.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F216927"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Germic | Oclovir</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Remantadin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Jin di na | Li an</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Remantadin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Remantadin | Rimantadine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Roflual</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Flumadine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Remantadin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Flumadine | Remantadin | Rimantadine Grindex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Remantadin | Rimantin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Flumadine | Rimantadine HCL</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Remantadin | Rimantadin avexima | Rimantadine | Rimantadine aktitab | Rimantadine sti | Rimantadine velfarm</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Remantadin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32900875">
<a name="32900875"></a>American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2020-2021. <i>Pediatrics</i>. 2020;146(4):e2020024588. doi:10.1542/peds.2020-024588<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/32900875/pubmed" id="32900875" target="_blank">32900875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3662473">
<a name="3662473"></a>Anderson EL, Van Voris LP, Bartram J, et al. Pharmacokinetics of a single dose of rimantadine in young adults and children. <i>Antimicrob Agents Chemother.</i> 1987;31(7):1140-1142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/3662473/pubmed" id="3662473" target="_blank">3662473</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bentley DW, Karki SD, and Betts RF, “Rimantadine and Seizures,” <i>Ann Intern Med</i>, 1989, 110(4):323-4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. “The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America”, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Antiviral Drugs: Information for Health Care Professionals. 2017. Available at <a href="https://www.cdc.gov/flu/professionals/antivirals/antiviral-dosage.htm" target="_blank">https://www.cdc.gov/flu/professionals/antivirals/antiviral-dosage.htm</a>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). CDC health update regarding treatment of patients with influenza with antiviral medications. January 9, 2015. Available at <a href="https://emergency.cdc.gov/han/han00375.asp%20" target="_blank">http://emergency.cdc.gov/han/han00375.asp </a>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Published November 30, 2020. Accessed December 31, 2020.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Influenza antiviral medications: summary for clinicians. <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm</a>. Last reviewed May 6, 2021. Accessed August 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21248682">
<a name="21248682"></a>Centers for Disease Control and Prevention (CDC), Influenza Division, National Center for Immunization and Respiratory Diseases. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Surveill Summ.</i> 2011;60(1):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/21248682/pubmed" id="21248682" target="_blank">21248682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12755288">
<a name="12755288"></a>Centers for Disease Control and Prevention (CDC), "Interim Guidance: Considerations Regarding 2009 Novel H1N1 Flu Virus in Intrapartum and Postpartum Hospital Settings," Available at <a href="https://www.cdc.gov/h1n1flu/guidance/obstetric.htm" target="_blank">http://www.cdc.gov/h1n1flu/guidance/obstetric.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/12755288/pubmed" id="12755288" target="_blank">12755288</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza. March 13, 2014. Available at <a href="https://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm" target="_blank">http://www.cdc.gov/flu/professionals/antivirals/avrec_ob2011.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7050702">
<a name="7050702"></a>Dolin R, Reichman RC, Madore HP, et al, “A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza A Infection,” <i>N Engl J Med</i>, 1982, 307(10):580-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/7050702/pubmed" id="7050702" target="_blank">7050702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2405270">
<a name="2405270"></a>Douglas RG Jr, “Prophylaxis and Treatment of Influenza,” <i>N Engl J Med</i>, 1990, 322(7):443-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/2405270/pubmed" id="2405270" target="_blank">2405270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8127252">
<a name="8127252"></a>“Drugs for Non-HIV Viral Infections,” <i>Med Lett Drugs Ther</i>, 1994, 36(919):27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/8127252/pubmed" id="8127252" target="_blank">8127252</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Flumadine (rimantadine hydrochloride) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; April 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7919641">
<a name="7919641"></a>Guay DR, “Amantadine and Rimantadine Prophylaxis of Influenza A in Nursing Homes,” <i>Drugs Aging</i>, 1994, 5(1):8-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/7919641/pubmed" id="7919641" target="_blank">7919641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1347578">
<a name="1347578"></a>Keating MR, “Antiviral Agents,” <i>Mayo Clin Proc</i>, 1992, 67(2):160-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/1347578/pubmed" id="1347578" target="_blank">1347578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21074132">
<a name="21074132"></a>Louie JK, Jamieson DJ, Rasmussen SA. 2009 pandemic influenza A (H1N1) virus infection in postpartum women in California. <i>Am J Obstet Gyneco</i>l. 2011;204(2):144.e1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/21074132/pubmed" id="21074132" target="_blank">21074132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6476812">
<a name="6476812"></a>Patriarca PA, Kater NA, Kendal AP, et al, “Safety of Prolonged Administration of Rimantadine Hydrochloride in the Prophylaxis of Influenza A Virus Infections in Nursing Homes,” <i>Antimicrob Agents Chemother</i>, 1984, 26(1):101-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/6476812/pubmed" id="6476812" target="_blank">6476812</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Rimantadine hydrochloride [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30566567">
<a name="30566567"></a>Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza a. <i>Clin Infect Dis</i>. 2019;68(6):e1-e47. doi: 10.1093/cid/ciy866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/30566567/pubmed" id="30566567" target="_blank">30566567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7606077">
<a name="7606077"></a>Wintermeyer SM and Nahata MC, “Rimantadine: A Clinical Perspective,” <i>Ann Pharmacother</i>, 1995, 29(3):299-310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/rimantadine-pediatric-drug-information/abstract-text/7606077/pubmed" id="7606077" target="_blank">7606077</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12769 Version 154.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
